Immunovia AB (LTS:0G8X) Long-Term Debt : kr0.00 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Immunovia AB Long-Term Debt?

Immunovia AB's Long-Term Debt for the quarter that ended in Dec. 2024 was kr0.00 Mil.

Immunovia AB Long-Term Debt Historical Data

The historical data trend for Immunovia AB's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB Long-Term Debt Chart

Immunovia AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

Immunovia AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Immunovia AB (LTS:0G8X) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Immunovia AB Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Immunovia AB's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovia AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (LTS:0G8X) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

IMMNOV:Sweden 1YR:Germany

Address

Medicon Village, Scheelevagen 8, Lund, SWE, 223 63

Website

https://www.immunovia.com

Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Immunovia AB Headlines

No Headlines